Neurology/CNS Phase 3 Deal Benchmarks — Ex-US

Understanding Neurology/CNS Deal Benchmarks at Phase 3

Phase 3 Neurology/CNS licensing deals in Ex-US territory command a median upfront payment of $232M, with values ranging from $141M at the low end to $344M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the neurology/cns therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $821M to $1.5B, with a median of $1.2B. Royalty rates for neurology/cns assets at this stage typically fall between 11.1% and 17% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.